ORKA — Oruka Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 907654 ·
Last close
$84.19
Market Cap
$5.57B
52W High
$115.52
52W Low
$15.77
ADV30
899,715
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -50,107,000 | -41,206,000 | 1,139,394,000 | 268,470,000 | 27,776,000 |
| Mar 2026 | 0 | — | -36,434,000 | -31,820,000 | 504,480,000 | 49,520,000 | 20,691,000 |
| Dec 2025 | 0 | — | -34,431,000 | -29,583,000 | 488,617,000 | 46,935,000 | 19,618,000 |
| Sep 2025 | 0 | — | -34,105,000 | -30,277,000 | 509,251,000 | 91,253,000 | 22,460,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-90,919,000
Investing CF
$-154,048,000
Financing CF
$210,915,000
CapEx
$-269,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.89
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-220,977,000
Inventory
—
Receivables
$0
ST Investments
$339,309,000
EBIT TTM
$-120,868,000
Pretax Income TTM
$-116,254,000
Interest Exp TTM
$0
Analysts
12
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,051,000 | -105,433,000 | 488,617,000 | 19,618,000 | 468,999,000 | -88,210,000 |
| Dec 2024 | — | — | — | 396,019,000 | 16,729,000 | 379,290,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.86
Max Pain — expiry 2026-11-20
max pain strike: $85.00 · spot: $84.19 · call oi: 3,448 · put oi: 116
Expected Move to 2026-11-20:
±$16.40
(19.48%) —
implied range
$67.79 –
$100.59
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | $5.53B | $31.86 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.50B | $65.95 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.71B | $87.96 | — |
| TVTX | Travere Therapeutics, Inc. | $5.80B | $61.57 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $6.26B | $314.10 | — |
News headlines (Yahoo Finance, 1h cache)
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
2026-09-24 17:02 · Yahoo
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
2026-09-24 00:16 · Yahoo
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
2026-09-23 12:52 · Yahoo
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
2026-09-23 11:00 · Yahoo
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
2026-09-09 20:01 · Yahoo
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
2026-08-24 20:01 · Yahoo
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
2026-07-01 21:23 · Yahoo
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
2026-06-27 19:48 · Yahoo
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
2026-06-24 21:44 · Yahoo
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
2026-06-10 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.